CEO Executive AssistantAn FDA advisory committee meeting is one of the highest-stakes events a pharmaceutical or biotech CEO will face. The committee’s vote is not binding, but it carries enormous weight with FDA reviewers, investors, prescribing physicians, and patient advocacy groups. A favorable vote can accelerate approval and confirm the commercial thesis. A negative vote can trigger a stock collapse, require additional clinical work, or in the worst cases, end a program.
The CEO’s preparation for an advisory committee meeting is not simply about knowing the data. It is about understanding the committee dynamics, positioning the program with the right framing, ensuring the board and investor base are properly set up for any outcome, and then managing the intense time demands of the preparation period without abandoning the rest of the business.
This article provides a detailed account of how effective pharma CEOs allocate their time in the 8 to 12 weeks before an adcom, what belongs to them versus their CMO and regulatory team, and how to manage the post-adcom period regardless of outcome.
The CEO’s Role Versus the CMO and Regulatory Team
Division of Preparation Responsibility
The most common mistake pharma CEOs make in adcom preparation is failing to define role boundaries clearly enough. Without explicit role clarity, preparation becomes chaotic: the CEO gets pulled into detailed slide edits that belong to the medical team, the CMO is uncertain which external experts the CEO wants personally briefed, and the regulatory team is not sure whether to escalate every FDA information request or handle them independently.
Effective adcom preparation requires the CEO to establish and hold the following division of responsibility at the outset.
The CMO and Chief Medical Officer own the clinical data presentation. They are responsible for the narrative integrity of the efficacy and safety data, the statistical analysis framing, and the clinical context that positions the benefit-risk profile in the most accurate and defensible way. The CEO does not edit clinical slides for scientific content; they review them for clarity and strategic framing.
The Chief Regulatory Officer and regulatory team own the FDA relationship during the preparation period. They manage the information exchange, respond to information requests, brief the CEO on any material FDA signals, and coordinate the logistics of the adcom briefing document submission. The CEO is informed and available for escalation, but does not micromanage FDA communications.
The CEO owns three things: the overall strategic positioning of the program, the external stakeholder management (board, investors, patient advocates, and key KOLs), and the final decisions on who attends the adcom and in what capacity.
What the CEO Presents at the Adcom
In many advisory committee meetings, the CEO does not present directly. The presentation is typically led by the CMO, Chief Medical Officer, and regulatory team, with subject-matter experts presenting specific data sections. The CEO may deliver an opening statement or participate in the open public hearing, but substantive data presentation belongs to the clinical and regulatory team.
This is appropriate, but it creates a specific preparation discipline requirement for the CEO: they need to be fully fluent in the program’s clinical story, benefit-risk profile, and the committee’s likely concerns without necessarily being the person presenting. Fluency without the presenter’s crutch of having prepared the slides requires more, not less, preparation time.
The 8-to-12-Week Preparation Timeline
Weeks 8 Through 6: Foundation Setting
Eight weeks before an adcom, the CEO’s primary task is to ensure the preparation structure is in place. This means confirming that a dedicated preparation team has been assembled, with clear roles and a preparation schedule that includes mock adcom sessions. It means engaging external regulatory advisors or former FDA officials who can provide independent perspective on how the committee is likely to approach the data. And it means initiating outreach to the company’s most important KOLs to ensure they are aware of the adcom, understand the clinical story, and are prepared to engage with the science publicly if appropriate.
The CEO should block recurring time in this period for two activities: weekly preparation updates with the regulatory and CMO team, and KOL engagement calls. Everything else in the calendar should be reviewed for what can be delegated or deferred.
An executive assistant who understands the adcom timeline can restructure the calendar proactively during this period. Routine internal meetings that the CEO attends out of habit rather than necessity should be delegated. Travel that is not adcom-related should be minimized in the final four weeks. For context on how to structure this kind of calendar protection, see the discussion of pharma CEO support.
Weeks 6 Through 4: Investor and Board Preparation
In the six to four week range before the adcom, the CEO shifts significant attention to the investor and board communication track. This is when the CEO should conduct one-on-one calls with the company’s most significant institutional shareholders to ensure they understand the data and have appropriate expectations about adcom dynamics.
Many shareholders, particularly generalist investors who have taken positions based on high-level program summaries, do not fully understand how advisory committees work. They may have inflated expectations for a favorable vote or insufficient appreciation for the uncertainty inherent in the process. The CEO who manages those expectations proactively before the adcom creates a more stable investor base capable of handling either outcome without panic.
Board preparation in this window involves at minimum a detailed adcom briefing to the full board, covering the clinical data, the committee composition and known perspectives of committee members, the likely questions or objections the committee may raise, and the CEO’s assessment of probable outcomes. The board should not be surprised by anything that happens at the adcom.
External advisors with regulatory expertise can provide valuable input during this period. The FDA’s advisory committee meeting information pages provide public context on how these committees are structured and how they operate.
Weeks 4 Through 2: Mock Adcom and Refinement
The mock adcom is the single most important preparation event in the entire timeline. Typically conducted four to two weeks before the actual adcom, a well-constructed mock brings in external experts, including former FDA advisors, physicians in the relevant therapeutic area, biostatisticians, and patient advocates, to simulate the committee’s review process.
The CEO should participate in the mock adcom, not as a presenter, but as an observer and strategist. Watching how external experts respond to the data presentation reveals gaps in the clinical narrative, likely committee objections, and opportunities to sharpen the benefit-risk framing before the actual meeting. Many CEOs report that the mock adcom is the most valuable investment of preparation time in the entire cycle.
The two weeks after the mock adcom are consumed by incorporating feedback, refining presentations, and conducting a second round of KOL and investor calls that are now informed by the mock adcom insights.
The Final Week: Logistics and Mental Preparation
The week immediately before an adcom is operationally intense. The briefing documents have been submitted, but travel logistics, hotel arrangements for the team, final rehearsals, and media preparation all require coordination. The CEO’s EA should own all of this logistics infrastructure so that the CEO is free to focus on the final rehearsal sessions and the stakeholder calls that will continue up to the day before.
The CEO should also use the final week to prepare for both outcomes. Investor call scripts, board communications, and internal employee communications for both a favorable and an unfavorable vote should be drafted and ready. Walking into the adcom with both scenarios scripted reduces the time-to-response after the vote and ensures the CEO is communicating from a position of preparation rather than reaction.
Managing Board and Investor Expectations During Preparation
The Expectation Calibration Problem
Advisory committee votes are genuinely uncertain. Committees composed of independent clinical experts can reach conclusions that diverge from the company’s view of the data, sometimes for reasons that reflect legitimate scientific disagreement and sometimes for reasons that reflect committee dynamics, presentation issues, or concerns the company did not anticipate.
Pharma CEOs who communicate this uncertainty clearly and consistently to their boards and investors throughout the preparation period create a more resilient stakeholder base. Those who allow optimistic narratives to take hold, and who do not actively manage expectations downward when the data warrant caution, set themselves up for relationship damage if the vote is unfavorable.
The CEO’s investor communication calendar during the preparation period should include specific conversations with major shareholders at the six-week and two-week marks, both calibrated to what is actually known at that point about the committee’s likely concerns.
Media and Public Communication Strategy
Adcom meetings are public events. The briefing documents submitted by both the company and FDA are published in advance. Patient advocates, physicians, and journalists follow these meetings closely. The CEO should have a media strategy in place before the adcom, including a decision on whether to do media interviews before or after the vote and what the key messages are in each scenario.
For companies with significant patient advocacy engagement, the CEO may choose to brief patient advocacy group leaders in the days before the adcom so they are prepared to respond publicly in a way that is informed and constructive.
Post-Adcom Time Management
If the Vote Is Favorable
A favorable advisory committee vote creates its own time management challenge. Investor interest accelerates, media requests increase, and the internal organization often needs leadership engagement to channel the momentum productively into the work that remains before actual FDA approval.
The CEO should have a scheduled series of investor calls ready to go within 48 hours of a favorable vote. Internal communications to employees should be ready to send the same day. And the regulatory team should be immediately re-engaged on any outstanding information requests from FDA that now move to the critical path.
The risk of a favorable vote is that the CEO invests the next several weeks in investor relations and public visibility at the expense of the operational work required to get to approval. A strong EA who can manage the surge of inbound requests while protecting the CEO’s time for the actual approval path is essential in this period.
If the Vote Is Unfavorable
An unfavorable vote is one of the most demanding situations a pharma CEO faces. The immediate priorities are: investor communications within hours (not days), a board call to assess the path forward, internal communications to the organization that acknowledge reality while maintaining direction, and a rapid assessment of whether and how the program can be salvaged.
The CEO’s time in the 48 to 72 hours after an unfavorable vote is almost entirely consumed by stakeholder management. The work of assessing the path forward begins in earnest in the first week after the vote, when the initial reaction period has stabilized and clear-headed analysis is possible.
Protecting time for that analysis, even amid the communication demands, is one of the most important things a pharma CEO can do in the post-adcom period. Understanding strategic thinking time is particularly relevant here: the weeks immediately after a difficult adcom vote are exactly when the CEO needs protected thinking time, and exactly when the calendar pressure to be reactive is most intense.
Conclusion: Pharma CEO FDA Advisory Committee Preparation as a Leadership Test
An advisory committee meeting is a leadership test as much as a scientific one. The CEOs who prepare most effectively are those who define their role clearly, invest their personal time in the stakeholder management that only they can do, and build the preparation infrastructure that allows their team to perform at the highest level.
Pharma CEO FDA advisory committee preparation requires a disciplined time architecture across 8 to 12 weeks, with clear milestones, protected preparation blocks, and a communication strategy that extends from the board to the investor base to the patient advocacy community. The CEOs who get this right are better positioned for a positive outcome, and far better positioned to manage the consequences of any outcome.
Related Reading
For further context, explore How Pharma CEOs Balance Regulatory Affairs and Commercial Time and How Pharma CEOs Manage Time During Major Conference Season.